The approval of Coartem Baby by Swiss authorities is a significant milestone in the fight against malaria, particularly for one of the most vulnerable populations with babies and very young children.
Coartem Baby is a specially formulated drug designed to treat malaria in infants who weigh between 2-5 kg, roughly covering newborns up to 6 months old. This is a major breakthrough because, until now, infants with malaria had to use adult or older child formulations, which increased the risk of overdose or improper dosing.
Active Ingredients: It contains artemether and lumefantrine, which work together to combat the malaria parasite. These two drugs are widely used in malaria treatment for older children and adults but have now been specially tailored for infants.
Formulation: The formulation is designed to dissolve easily, even when mixed with breast milk, making it easier to administer. Additionally, it has a sweet cherry flavour to encourage better acceptance by infants.
Safety & Accuracy: By providing a dosage specifically for infants, the risk of overdose is minimized. This is crucial, as malaria treatment can often be complicated for the youngest children due to their smaller size and different metabolic rates.
Developed by Novartis in partnership with Medicines for Malaria Venture (MMV) and supported by international governments and organizations such as the UK, Switzerland, Netherlands, the World Bank, and the Rockefeller Foundation.
Clinical Trials: The drug underwent assessments and clinical trials in eight African countries—Burkina Faso, Ivory Coast, Kenya, Malawi, Mozambique, Nigeria, Tanzania, and Uganda—which are some of the most malaria-endemic areas in the world.
Targeting a Vulnerable Group: Infants are among the most vulnerable to malaria. The disease can be fatal for babies, especially in regions where healthcare access is limited. Coartem Baby’s approval is a huge step toward providing life-saving treatment for this group.
Reducing Overdose Risk: Prior to Coartem Baby, infants had to rely on formulations meant for older children or adults. This often led to inappropriate dosing, increasing the risk of side effects or overdose. Coartem Baby eliminates this risk with its carefully adjusted formulation.
Ease of Administration: The fact that the drug dissolves easily in breast milk, combined with its sweet flavour, will make it much easier for caregivers to administer the medicine, improving adherence and treatment outcomes.
Malaria remains one of the most deadly infectious diseases, particularly in tropical and subtropical regions. While significant progress has been made in reducing malaria rates, the disease still poses a serious health threat, especially for young children under five, pregnant women, and people living in malaria-endemic areas.
Transmission: Malaria is caused by Plasmodium parasites transmitted through the bite of an infected female Anopheles mosquito.
Not Contagious: Malaria is not contagious from person to person but can be spread through infected blood or contaminated needles.
Most Dangerous Species: The two most dangerous malaria-causing species are Plasmodium falciparum and Plasmodium vivax.
Early Symptoms: Fever, chills, and headaches usually appear 10–15 days after infection.
Severe Symptoms: Without treatment, severe malaria can lead to complications such as seizures, difficulty breathing, jaundice, dark urine, and death.
Partial Immunity: People living in endemic regions can develop partial immunity over time, which can make the diagnosis difficult since their symptoms may be less severe.
The approval of Coartem Baby is a significant leap forward in malaria treatment, addressing a critical gap in the healthcare options available for infants. By making the treatment safer and more effective for babies, this drug has the potential to save countless lives and contribute to the global effort to eliminate malaria.
We provide offline, online and recorded lectures in the same amount.
Every aspirant is unique and the mentoring is customised according to the strengths and weaknesses of the aspirant.
In every Lecture. Director Sir will provide conceptual understanding with around 800 Mindmaps.
We provide you the best and Comprehensive content which comes directly or indirectly in UPSC Exam.
If you haven’t created your account yet, please Login HERE !
We provide offline, online and recorded lectures in the same amount.
Every aspirant is unique and the mentoring is customised according to the strengths and weaknesses of the aspirant.
In every Lecture. Director Sir will provide conceptual understanding with around 800 Mindmaps.
We provide you the best and Comprehensive content which comes directly or indirectly in UPSC Exam.
Offline/Online Class